Sang‐We Kim
A5046400988- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Cancer therapeutics and mechanisms
- Brain Metastases and Treatment
- Pancreatic and Hepatic Oncology Research
- Peptidase Inhibition and Analysis
- Radiomics and Machine Learning in Medical Imaging
- PI3K/AKT/mTOR signaling in cancer
- Medical Imaging Techniques and Applications
- RNA modifications and cancer
- Lymphoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
- Advanced Breast Cancer Therapies
- Neuroendocrine Tumor Research Advances
- Hepatocellular Carcinoma Treatment and Prognosis
- Chronic Lymphocytic Leukemia Research
- PARP inhibition in cancer therapy
University of Ulsan
2016-2025
Asan Medical Center
2016-2025
Ulsan College
2016-2025
Samsung Medical Center
2007-2024
Chris O’Brien Lifehouse
2024
Seoul National University Bundang Hospital
2024
Chungbuk National University Hospital
2024
Yonsei University
2024
National Cancer Institute
2024
Seoul Medical Center
2014-2023
In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better nivolumab plus ipilimumab than monotherapy, particularly among tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess long-term benefit of in NSCLC.
Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant are unknown.
Gefitinib has shown high response rate and improved progression-free survival (PFS) in never-smokers with lung adenocarcinoma (NSLAs). We compared efficacy of gefitinib gemcitabine cisplatin (GP) chemotherapy this group patients as first-line therapy.In randomized phase III trial, a total 313 Korean stage IIIB or IV adenocarcinoma, Eastern Cooperative Oncology Group performance status 0 to 2, adequate organ function were randomly assigned receive either (250 mg daily) GP (gemcitabine 1,250...
Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)–rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluated two regimens of brigatinib, an investigational next-generation ALK inhibitor, in crizotinib-refractory ALK-positive NSCLC. Patients and Methods were stratified by brain metastases best response to crizotinib. They randomly assigned (1:1) oral brigatinib 90 mg once daily (arm A) or 180 a 7-day...
Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody immune cell-directing activity, binds each receptor's extracellular domain, bypassing at the inhibitor binding site.CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included population EGFR Exon20ins NSCLC. The primary end...
PURPOSE The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D CT) (D versus alone (CT) in first-line metastatic non–small-cell lung cancer (mNSCLC). METHODS Patients (n = 1,013) with EGFR/ ALK wild-type mNSCLC were randomly assigned (1:1:1) to 75 mg 1,500 platinum-based for up four 21-day cycles, followed by once every 4 weeks until progression one additional dose; progression; or six cycles (with without maintenance pemetrexed; all arms)....
IntroductionIn CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) less (prespecified descriptive analysis). We report results minimum 4 years' follow-up.MethodsAdults previously untreated stage IV recurrent NSCLC were randomized (1:1:1) ipilimumab, nivolumab, (PD-L1 ≥1%); chemotherapy, <1%). Efficacy included OS and other measures. Safety timing...
Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that selective for EGFR-TKI-sensitizing and
<h3>Importance</h3> Metastatic non–small cell lung cancer (mNSCLC) with<i>EGFR</i>exon 20 insertion (<i>EGFR</i>ex20ins) mutations is associated with a poor prognosis. Mobocertinib an oral tyrosine kinase inhibitor designed to selectively target<i>EGFR</i>ex20ins mutations. <h3>Objective</h3> To evaluate treatment outcomes and safety of mobocertinib in patients previously treated<i>EGFR</i>ex20ins-positive mNSCLC. <h3>Design, Setting, Participants</h3> This 3-part, open-label, phase 1/2...
The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non-small-cell lung cancer (NSCLC) after complete tumor resection (DFS hazard ratio [HR], 0.20 [99.12% CI, 0.14 to 0.30];
Amivantamab has been approved for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) epidermal growth factor receptor (
Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd has not been evaluated patients with previously treated human epidermal growth factor receptor 2-mutant (
Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found have a clinically meaningful improvement disease-free survival (DFS) IB EGFR-mutated (EGFRm) NSCLC. Here, we report prespecified and exploratory analyses of adjuvant use outcomes from ADAURA.Patients EGFRm NSCLC were randomized 1:1 receive or placebo for years. before randomization not...
Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung cancers but not a known mechanism of resistance to EGFR inhibitors. HER3-DXd an antibody-drug conjugate consisting HER3 antibody attached topoisomerase I inhibitor payload via tetrapeptide-based cleavable linker. This phase I, dose escalation/expansion study included patients with locally advanced or metastatic non-small cell cancer (NSCLC) prior tyrosine (TKI) therapy. Among 57 receiving 5.6 mg/kg...
MET-inhibitor and EGFR tyrosine kinase inhibitor (EGFR-TKI) combination therapy could overcome acquired MET-mediated osimertinib resistance. We present the final phase Ib TATTON (NCT02143466) analysis (Part B, n = 138/Part D, 42) assessing oral savolitinib 600 mg/300 mg once daily (q.d.) + 80 q.d. in patients with MET-amplified, EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) progression on prior EGFR-TKI. An acceptable safety profile was observed. In Parts B respectively,...
BackgroundAmivantamab plus lazertinib (amivantamab–lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal growth factor receptor)–mutated advanced non–small-cell lung cancer (NSCLC).MethodsIn a phase 3, international, randomized trial, we assigned, 2:2:1 ratio, EGFR-mutated (exon 19 deletion L858R), locally metastatic NSCLC to receive amivantamab–lazertinib (in an open-label fashion),...
The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of fusion–positive non–small-cell lung cancer (NSCLC) have antitumor activity, but resistance develops in tumors, and intracranial activity is suboptimal. Repotrectinib a next-generation TKI with preclinical against cancers, including those mutations such as G2032R. Download PDF Research Summary. In this registrational phase 1–2 trial, we assessed efficacy safety repotrectinib patients advanced...
PURPOSE In the treatment of non–small-cell lung cancer (NSCLC) with a driver mutation, role anti–PD-(L)1 antibody after tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase III study evaluates efficacy atezolizumab plus bevacizumab, paclitaxel, and carboplatin (ABCP ) in EGFR- or ALK-rearranged translocated NSCLC upon progression on TKI therapy. MATERIALS AND METHODS We compared clinical ABCP followed by maintenance therapy bevacizumab pemetrexed...
PURPOSE The phase III CheckMate 722 trial (ClinicalTrials.gov identifier: NCT02864251 ) evaluated nivolumab plus chemotherapy versus in patients with epidermal growth factor receptor ( EGFR)–mutated metastatic non–small-cell lung cancer (NSCLC) after disease progression on EGFR tyrosine kinase inhibitors (TKIs). METHODS Patients first- or second-generation TKI therapy (without T790M mutation) osimertinib (with/without were randomly assigned 1:1 to (360 mg once every 3 weeks) platinum-doublet...
Abstract Patients with epidermal growth factor receptor ( EGFR )-mutated non-small cell lung cancer (NSCLC) often develop resistance to current standard third-generation tyrosine kinase inhibitors (TKIs); no targeted treatments are approved in the osimertinib-relapsed setting. In this open-label, dose-escalation and dose-expansion phase 1 trial, potential for improved anti-tumor activity by combining amivantamab, an EGFR-MET bispecific antibody, lazertinib, a TKI, was evaluated patients...